Healthy Clinical Trial
— FROMAGEOfficial title:
Study of the Impact of Cheese Matrix on Postprandial Lipemia: a Clinical Study
| Verified date | August 2017 |
| Source | Laval University |
| Contact | n/a |
| Is FDA regulated | No |
| Health authority | |
| Study type | Interventional |
Dairy products consumption is widely recommended in a healthy diet not only for bone growth
and maintenance, but also as a protein, calcium and magnesium sources for an adequate diet.
However, dairy products are a major dietary source of saturated fat that is associated with
increased risk of coronary heart disease. ln this context, dietary guidelines still advocate
a restriction in dietary saturated fat for optimal heart health. Nevertheless, the
association between saturated fat and the risk of heart disease remains highly controversial
within the scientific community. There is also emerging evidence that the impact of dietary
saturated fat will be significantly influenced by the food matrix through which it is
provided. Recent studies indicate that cheese could have a major influence on intestinal fat
absorption and the magnitude of the after meal release of fat in blood circulation. This is
of interest because substantial evidence exists indicating that elevated levels of the after
meal fat levels are associated with increased cardiovascular risk. Therefore, the improvement
of the after meal fat levels produced by cheese consumption could well be part of novel
therapeutic approaches contributing to improve cardiovascular risk.
The general objective of the proposed research is to investigate how cheese consumption
affects the after meal release of fat in blood circulation in healthy subjects. Our
hypothesis is that, compared to butter, cheese consumption will have a beneficial impact on
the after meal fat levels in healthy subjects. Favourable results from the proposed study
will provide novel and much warranted evidence on the importance of considering changes in
the after meal fat levels, not only bad cholesterol, as part of the on-going saturated
fat-heart disease debate and that cheese should indeed be part of a healthy diet.
| Status | Completed |
| Enrollment | 40 |
| Est. completion date | September 2016 |
| Est. primary completion date | June 2016 |
| Accepts healthy volunteers | Accepts Healthy Volunteers |
| Gender | All |
| Age group | 18 Years to 65 Years |
| Eligibility |
Inclusion Criteria: - Age between 18-65 years (men and women) Exclusion Criteria: - Smokers (more than 1 cigarette/d) - Body weight variation more than 10% during the last 6 months prior to the study baseline - BMI more than 35 kg/m2 - Previous history of cardiovascular disease - Subjects with type 2 diabetes - Subjects with monogenic dyslipidemia - Subjects taking anti-inflammatory drugs - Subjects with endocrine or gastrointestinal disease - Allergy/intolerance to dairy - Clinical use of vitamin D and calcium supplements - Vegetarians - Subjects who are in situation or have a condition that, in the opinion of the investigators, may interfere with optimal participation in the study |
| Country | Name | City | State |
|---|---|---|---|
| Canada | Institute of Nutrition and Functional Foods (INAF) | Quebec |
| Lead Sponsor | Collaborator |
|---|---|
| Laval University |
Canada,
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | Change in triglyceride concentrations 4h following the test meals ingestion | At week 0, week 2 and week 4 (at the end of the three test meals). | ||
| Secondary | Change in triglyceride concentrations (area under the curve) following the test meals ingestion | At week 0, week 2 and week 4 (at the end of the three test meals). | ||
| Secondary | Change in free fatty acids concentrations (area under the curve) following the test meals ingestion | At week 0, week 2 and week 4 (at the end of the three test meals). | ||
| Secondary | Change in apolipoprotein B48 concentrations (area under the curve) following the test meals ingestion | At week 0, week 2 and week 4 (at the end of the three test meals). |
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT06052553 -
A Study of TopSpin360 Training Device
|
N/A | |
| Completed |
NCT05511077 -
Biomarkers of Oat Product Intake: The BiOAT Marker Study
|
N/A | |
| Recruiting |
NCT04632485 -
Early Detection of Vascular Dysfunction Using Biomarkers From Lagrangian Carotid Strain Imaging
|
||
| Completed |
NCT05931237 -
Cranberry Flavan-3-ols Consumption and Gut Microbiota in Healthy Adults
|
N/A | |
| Completed |
NCT04527718 -
Study of the Safety, Tolerability and Pharmacokinetics of 611 in Adult Healthy Volunteers
|
Phase 1 | |
| Terminated |
NCT04556032 -
Effects of Ergothioneine on Cognition, Mood, and Sleep in Healthy Adult Men and Women
|
N/A | |
| Completed |
NCT04998695 -
Health Effects of Consuming Olive Pomace Oil
|
N/A | |
| Completed |
NCT04107441 -
AX-8 Drug Safety, Tolerability and Plasma Levels in Healthy Subjects
|
Phase 1 | |
| Completed |
NCT04065295 -
A Study to Test How Well Healthy Men Tolerate Different Doses of BI 1356225
|
Phase 1 | |
| Completed |
NCT01442831 -
Evaluate the Absorption, Metabolism, And Excretion Of Orally Administered [14C] TR 701 In Healthy Adult Male Subjects
|
Phase 1 | |
| Terminated |
NCT05934942 -
A Study in Healthy Women to Test Whether BI 1358894 Influences the Amount of a Contraceptive in the Blood
|
Phase 1 | |
| Recruiting |
NCT05525845 -
Studying the Hedonic and Homeostatic Regulation of Food Intake Using Functional MRI
|
N/A | |
| Completed |
NCT05515328 -
A Study in Healthy Men to Test How BI 685509 is Processed in the Body
|
Phase 1 | |
| Completed |
NCT05030857 -
Drug-drug Interaction and Food-effect Study With GLPG4716 and Midazolam in Healthy Subjects
|
Phase 1 | |
| Completed |
NCT04967157 -
Cognitive Effects of Citicoline on Attention in Healthy Men and Women
|
N/A | |
| Recruiting |
NCT04714294 -
Evaluate the Safety, Tolerability and Pharmacokinetics Characteristics of HPP737 in Healthy Volunteers
|
Phase 1 | |
| Recruiting |
NCT04494269 -
A Study to Evaluate Pharmacokinetics and Safety of Tegoprazan in Subjects With Hepatic Impairment and Healthy Controls
|
Phase 1 | |
| Completed |
NCT04539756 -
Writing Activities and Emotions
|
N/A | |
| Recruiting |
NCT04098510 -
Concentration of MitoQ in Human Skeletal Muscle
|
N/A | |
| Completed |
NCT03308110 -
Bioavailability and Food Effect Study of Two Formulations of PF-06650833
|
Phase 1 |